Compare TWIN & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWIN | XOMA |
|---|---|---|
| Founded | 1918 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 308.6M |
| IPO Year | 1994 | N/A |
| Metric | TWIN | XOMA |
|---|---|---|
| Price | $16.87 | $34.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $60.60 |
| AVG Volume (30 Days) | 28.5K | ★ 101.1K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.53 | N/A |
| Revenue | ★ $340,738,000.00 | N/A |
| Revenue This Year | $10.79 | $24.59 |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | ★ $10.31 | $29.64 |
| Revenue Growth | ★ 15.45 | N/A |
| 52 Week Low | $6.16 | $19.33 |
| 52 Week High | $19.63 | $39.92 |
| Indicator | TWIN | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 58.55 | 79.69 |
| Support Level | $14.72 | $32.73 |
| Resistance Level | $19.16 | $35.17 |
| Average True Range (ATR) | 0.87 | 1.58 |
| MACD | 0.21 | 0.49 |
| Stochastic Oscillator | 83.83 | 93.90 |
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.